VOY-101 for Age-Related Macular Degeneration

Recruiting in Palo Alto (17 mi)

+2 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Perceive Biotherapeutics, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial tests the safety of VOY-101, an eye injection, in patients with severe AMD that doesn't involve abnormal blood vessel growth. The goal is to see if this treatment can help manage their condition.

Eligibility Criteria

This trial is for individuals over 50 with advanced non-neovascular age-related macular degeneration (AMD). Participants must be able to understand the study, provide consent, and commit to follow-up visits. They should have a specific form of AMD without signs of certain complications and meet genetic risk criteria.

Inclusion Criteria

Are willing and able to understand and provide written informed consent.

Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.

I have advanced AMD without any signs of MNV.

+5 more

Exclusion Criteria

I do not have any other major health, eye, or inherited conditions.

I am not pregnant and willing to use effective birth control during the study.

Participant Groups

The study tests VOY-101 in patients with AMD. It starts by finding the highest dose people can tolerate without too many side effects (dose escalation), then compares that dose to a lower one and a control group to see which works best.

3Treatment groups

Experimental Treatment

Group I: Mid DoseExperimental Treatment1 Intervention

VOY-101 Mid Dose (single dose, IVT)

Group II: Low DoseExperimental Treatment1 Intervention

VOY-101 Low Dose (single dose, IVT)

Group III: High DoseExperimental Treatment1 Intervention

VOY-101 High Dose (single dose, IVT)